Xbrane Biopharma AB: Oxford Nanopore Technologies licenses Xbrane Biopharma’s protein production technology




Press Release

Oxford Nanopore Technologies licenses Xbrane Biopharma's protein production technology

Xbrane Biopharma AB has entered into a licence agreement with Oxford Nanopore Technologies regarding Xbrane's technology for the production of proteins used within Oxford Nanopore Technologies DNA sequencing technology. The compensation for the agreement is an un-disclosed annual license fee.

"We are very pleased to have reached an agreement with Oxford Nanopore Technologies, one of the worlds leading companies within DNA sequencing technology. Xbrane's superior technology will be used for producing important proteins to be used for enabling the DNA sequencing in Oxford Nanopore Technologies' DNA sequencing technology. This agreement demonstrates the versatility of Xbrane's technology and the opportunities that exists within other types of industrial applications", says Martin Åmark, CEO of Xbrane Biopharma AB.

"We are delighted to be collaborating with Xbrane on this technology component," said Dr Gordon Sanghera, CEO of Oxford Nanopore.  " The MinION portable DNA sequencing device is now in broad use in many research areas, including pathogen analysis, antimicrobial resistance, environmental analyses, metagenomics, cancer research and even education and relies on a highly sophisticated combination of technologies to provide real time biological information to scientists." Oxford Nanopore produces the only portable, real time DNA and RNA sequencer: the MinION.  For more information on the applications of the technology visit https:/publications.nanoporetech.com.

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing generics for injectable controlled release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company's portfolio of High Demand Complex Generics. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information seewww.xbrane.com.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

About Oxford Nanopore Technologies
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Now commercially available, the MinION is in use by a thriving community of more than 1,000 people in 34 countries, it is enabling myriad applications within the traditional laboratory environment and in the field.

Nanopore sensing technology is fully scalable and the high-throughput, high-sample number PromethION is currently being prepared for release in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute library prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to convert complex samples such as blood, saliva or environmental samples directly onto a nanopore sensing device.

Metrichor offers analysis solutions coupled with nanopore sensing devices, with the goal of making analyses accessible to people without bioinformatics skills or even biology qualifications. Nanopore devices can be adapted for the analysis of a range of biological molecules including DNA, RNA and proteins. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores. For more information seewww.nanoporetech.com

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 August 8 2016.

Oxford Nanopore Technologies licenses Xbrane Biopharma technology

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Xbrane Biopharma AB via Globenewswire